More than 15,000 vaccine doses administered yesterday;
88 in hospital & 6 in ICU; 1 death; 215 cases
发稿单位：新西兰卫生部
发稿时间：23 November 2021
撰 稿 者：同发稿单位
原文连结：https://bit.ly/3xeoQ4i
COVID-19单位：https://covid19.govt.nz/
统计网页：https://bit.ly/3D5GSI5
病例 https://bit.ly/3qwLfZD
疫苗施打：https://bit.ly/3HnbrvN
There were 15,224 first and second vaccine doses administered yesterday, made
up of 4,777 first doses and 10,447 second doses. To date, 91% of eligible
people in New Zealand have had their first dose and 84% are fully vaccinated.
As of 10.30am today, more than 1,470,000 million requests for a My Vaccine
Pass had been processed.
资格人口=全人口-不符合疫苗施打条件的人
疫苗施打状况(依据资格人口百分比)：
(全国)
总计 7,366,916 剂：3,846,920 第一剂(91%)、3,519,996 第二剂(84%)
昨日 15,224 剂： 4,777 第一剂 、 10,447 第二剂
(毛利人、太平洋原住民、各大区卫生局疫苗施打状况详见相关连结)
医院病例状况
目前总计有88名(+3)病例住院：
North Shore：19 (Waitemata)
Middlemore ：29
Auckland ：37
Waikato ： 2
Rotorua ： 1
住院病例的平均年龄是45岁
6名(+1)住ICU/HDU。
住院病例中有16名病例是突破性感染(11/23更新)
(Northern Region wards only as of 17 November)
新西兰本波爆发至今 7,268 例
新西兰疫情开始至今10,025 例
新西兰七日平均185位病例
新西兰今日新增218位病例：
北岛
Auckland(奥克兰) 6,756例(+196 含康复者2,281例)
Waikato (怀卡多)*** 361例(+ 11 含康复者 106例)
Wellington(威灵顿) 18例( 含康复者 17例)
Northland (北地) 70例(+ 4 含康复者 39例)
Bay of Plenty(富饶湾) 18例(+ 1 )
Lakes 24例(+ 2 )
Taranaki 6例(全员康复)
MidCentral* 4例(+ 1 )
Wairarapa 3例( )
南岛
Nelson/Marlborough 1例(已康复)
Canterbury 7例( 含康复者 3例)
*昨日保底病例加入今日统计
***两例改判不是病例
疫苗通行证持续推广中
死亡案例通报：
疫情至今死亡案例通报目前41例
本波爆发死亡案例通报目前15例：
14本土(医院10(+1)、隔离(MIQ、居家等)3、待查1)
1境外移入
Auckland City Hospital通报一名50多岁病例死亡。
11/17送医，今日死亡回报
Clarification on COVID-19 testing, immigration status(略)
Third primary vaccine dose for immunocompromised patients
针对免疫力低下的病人要打第三剂疫苗
(这边的用词是Third primary vaccine dose 不是booster doses)
Updated advice from the COVID-19 Vaccine Technical Advisory Group (CVTAG) on
the third primary dose for immunocompromised patients has been published on
the Ministry of Health website.
In October, a third primary dose of the Pfizer vaccine was recommended for
individuals who are severely immunocompromised, because they are at higher
risk of severe outcomes from COVID-19 and might not produce a sufficiently
strong immune response after two doses of the vaccine.
Updated CV TAG recommendations include information about the individuals who
should be offered a third primary dose, with dialysis patients now eligible
along with the groups already identified. Guidance on how to accommodate
biologics and immunosuppressive therapies has also been added and dosage
thresholds removed to support clinical discretion.
Advice for clinicians on the guidance is available through the Immunisation
Advisory Centre, and this information will be updated periodically through
the Immunisation Handbook.
A third primary dose for severely immunocompromised people different from a
booster. A third primary dose of the Pfizer COVID-19 vaccine for severely
immunocompromised people is off-label usage and includes prescription and
consent obligations on the prescriber, the vaccinator, and the patient.
地区更新略